Agenus (NASDAQ:AGEN) Posts Quarterly Earnings Results, Beats Expectations By $0.58 EPS

Agenus (NASDAQ:AGEN) released its quarterly earnings results on Monday. The biotechnology company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.61) by $0.58, Zacks reports. The business had revenue of $24.07 million for the quarter, compared to analysts’ expectations of $26.38 million.

Agenus Price Performance

AGEN stock opened at $3.38 on Wednesday. Agenus has a 1-year low of $1.38 and a 1-year high of $19.69. The company has a market capitalization of $71.56 million, a price-to-earnings ratio of -0.30 and a beta of 1.48. The business has a 50 day simple moving average of $2.17 and a two-hundred day simple moving average of $2.91.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on AGEN shares. Robert W. Baird upped their price target on shares of Agenus from $3.00 to $4.00 and gave the company a “neutral” rating in a research report on Tuesday. B. Riley reiterated a “buy” rating on shares of Agenus in a research note on Monday, April 21st. StockNews.com upgraded Agenus from a “sell” rating to a “hold” rating in a research note on Friday, March 21st. Finally, HC Wainwright reiterated a “neutral” rating on shares of Agenus in a research note on Tuesday. Six analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Agenus presently has a consensus rating of “Hold” and a consensus target price of $9.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Agenus stock. Invesco Ltd. acquired a new position in shares of Agenus Inc. (NASDAQ:AGEN) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 58,281 shares of the biotechnology company’s stock, valued at approximately $88,000. Invesco Ltd. owned approximately 0.28% of Agenus at the end of the most recent reporting period. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.